“…Compounds such as 34, 61, and 103 act synergistically in combination with commercially available antimycobacterial agents and are paving the way as a new option for multidrug treatment. Compounds 22,23,40,47, and 48 were effective against intracellular dormant bacilli. This review also highlighted some new sites and compounds (40,41,42,55,56,57,61,82, and 103) for drug action, which determine survival of the bacilli.…”